logo
logo

Weave Bio secures $20M Series A funding to enhance its AI-native regulatory platform, led by USVP.

Oct 16, 20255 days ago

Amount Raised

$20 Million

Round Type

series a

San FranciscoArtificial IntelligenceBiotechnology

Investors

Serrado CapitalTmvCharacterMagnetic VenturesInnovation EndeavorsUsvp

Description

Weave Bio, a pioneer in AI-native regulatory automation management solutions, announced its $20 million Series A funding. The round was led by USVP, with several other investors participating. This funding will help expand the reach and capabilities of Weave's platform, designed for regulatory workflows in the pharmaceutical sector. With a total of $36 million raised, Weave aims to enhance quality and reduce operational costs for its clients.

Company Information

Company

Weave Bio

Location

San Francisco, California, United States

About

Weave Bio is an AI-native, cloud-based, software company redesigning regulatory workflows and transforming how novel therapies navigate the complex path from lab to market. The Weave Platform is an end-to-end solution that streamlines regulatory content preparation and lifecycle management for pharmaceutical companies, biotech firms, CROs, and regulatory consultants. Weave infuses AI into every step of the workflow, from data extraction to authoring to review and data verification, to yield compliant, submission-ready regulatory dossiers with unprecedented speed.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech